Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-cont
Note: employees of the Institute are marked with an asterisk (*) in the list of authors.
Web of Science ,
Scopus
Authors
Halperin S.A., Ye L., MacKinnon-Cameron D., Smith B., Cahn P.E., Ruiz-Palacios G.M., Ikram A., Lanas F., Guerrero M.L., Navarro S.R.M., Sued O., * Lioznov D.A., Dzutseva V., Parveen G., Zhu F., Leppan L., Langley J.M., Barreto L., Gou J., Zhu T., Mao H., Rozhkova* E., Zubkova* T.
Publication type
Journal article
Indexed in
Web of Science ,
Scopus Info:
Published in
The Lancet
Year of publication
2022
Volume
399
Number
10321
Pages
237-248